# Knowledge Index

> Content catalog of the OpenEndo knowledge base. Read this first.
> Last updated: 2026-09-02 | Total pages: 6

## Entities

- [[ryeqo]] — relugolix combo pill; EU-approved for endometriosis (2023); generelt tilskud in DK
- [[yselty]] — linzagolix; EU-approved (Dec 2024); DK availability still unverified
- [[hmi-115]] — first non-hormonal therapy in Phase 3 (anti-PRLR antibody)

## Concepts

- [[gnrh-antagonists]] — mechanism, add-back therapy, the class behind Ryeqo/Yselty
- [[saliva-diagnostics]] — non-invasive testing (Ziwig Endotest) vs 7–10-year diagnostic delay

## Comparisons

- [[ryeqo-vs-yselty]] — head-to-head on evidence, dosing, add-back and Danish access

## Queries

_(none yet — file valuable answers here)_